These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 26304885)

  • 41. Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
    Østgård LSG; Nørgaard M; Pedersen L; Østgård RD; Medeiros BC; Overgaard UM; Schöllkopf C; Severinsen M; Marcher CW; Jensen MK
    Br J Haematol; 2018 Apr; 181(2):205-214. PubMed ID: 29504124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.
    Lazarevic V; Hörstedt AS; Johansson B; Antunovic P; Billström R; Derolf Å; Lehmann S; Möllgård L; Peterson S; Stockelberg D; Uggla B; Vennström L; Wahlin A; Höglund M; Juliusson G
    Eur J Haematol; 2015 May; 94(5):419-23. PubMed ID: 25200361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
    Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reasons for treating secondary AML as de novo AML.
    Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
    Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.
    Østgård LS; Nørgaard M; Sengeløv H; Medeiros BC; Kjeldsen L; Overgaard UM; Severinsen MT; Marcher CW; Jensen MK; Nørgaard JM
    Oncotarget; 2016 Nov; 7(44):72044-72056. PubMed ID: 27732947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
    Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
    Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
    Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lipton JH; Loach D; Seftel MD; Uhm J; Alam N; Lambie A; McGillis L; Messner HA
    Bone Marrow Transplant; 2015 Jul; 50(7):907-13. PubMed ID: 25822226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
    Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH
    Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
    Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
    Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
    Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
    Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
    Ossenkoppele G; Montesinos P
    Crit Rev Oncol Hematol; 2019 Jun; 138():6-13. PubMed ID: 31092386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation.
    De Witte T; Van Biezen A; Hermans J; Labopin M; Runde V; Or R; Meloni G; Mauri SB; Carella A; Apperley J; Gratwohl A; Laporte JP
    Blood; 1997 Nov; 90(10):3853-7. PubMed ID: 9354651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
    Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
    Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison of chromosome karyotype between myelodysplastic syndrome and acute leukemia patients confirmed at the same period].
    Jiang M; Wen BZ; Li L; Chen S; Cheng H; Hao JP; Chen R; Wang L; Zhao F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):387-92. PubMed ID: 24763010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation.
    Barnard DR; Lange B; Alonzo TA; Buckley J; Kobrinsky JN; Gold S; Neudorf S; Sanders J; Burden L; Woods WG
    Blood; 2002 Jul; 100(2):427-34. PubMed ID: 12091332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.
    Micallef IN; Lillington DM; Apostolidis J; Amess JA; Neat M; Matthews J; Clark T; Foran JM; Salam A; Lister TA; Rohatiner AZ
    J Clin Oncol; 2000 Mar; 18(5):947-55. PubMed ID: 10694543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.